(Q37448927)

20 August 2017

1 reference

title

Targeting the mTOR pathway using deforolimus in cancer therapy (English)

1 reference

20 August 2017

author name string

Devalingam Mahalingam

1

1 reference

20 August 2017

Kamalesh Sankhala

2

1 reference

20 August 2017

Alain Mita

3

1 reference

20 August 2017

Francis J Giles

4

1 reference

20 August 2017

Monica M Mita

5

1 reference

20 August 2017

language of work or name

English

0 references

publication date

1 April 2009

1 reference

20 August 2017

1 reference

20 August 2017

volume

5

1 reference

20 August 2017

issue

3

1 reference

20 August 2017

page(s)

291-303

1 reference

mTOR controls cell cycle progression through its cell growth effectors S6K1 and 4E-BP1/eukaryotic translation initiation factor 4E

20 August 2017

cites work

1 reference

TOR, a central controller of cell growth

21 January 2018

1 reference

Exploiting the PI3K/AKT pathway for cancer drug discovery

21 January 2018

1 reference

The epidermal growth factor receptor pathway: a model for targeted therapy

21 January 2018

1 reference

Role of the insulin-like growth factor family in cancer development and progression

21 January 2018

1 reference

TOR signaling in growth and metabolism

21 January 2018

1 reference

A mammalian protein targeted by G1-arresting rapamycin-receptor complex

21 January 2018

1 reference

Role of mTOR in anticancer drug resistance: perspectives for improved drug treatment

21 January 2018

1 reference

Targets for Cell Cycle Arrest by the Immunosuppressant Rapamycin in Yeast

21 January 2018

1 reference

mTOR and cancer: insights into a complex relationship

21 January 2018

1 reference

Two TOR complexes, only one of which is rapamycin sensitive, have distinct roles in cell growth control

21 January 2018

1 reference

Rapamycin derivatives reduce mTORC2 signaling and inhibit AKT activation in AML.

21 January 2018

1 reference

mTOR interacts with raptor to form a nutrient-sensitive complex that signals to the cell growth machinery

21 January 2018

1 reference

Raptor, a binding partner of target of rapamycin (TOR), mediates TOR action

21 January 2018

1 reference

Raptor, a binding partner of target of rapamycin

21 January 2018

1 reference

The mammalian target of rapamycin (mTOR) partner, raptor, binds the mTOR substrates p70 S6 kinase and 4E-BP1 through their TOR signaling (TOS) motif

21 January 2018

1 reference

Suppression of the mTOR-raptor signaling pathway by the inhibitor of heat shock protein 90 geldanamycin

21 January 2018

1 reference

GbetaL, a positive regulator of the rapamycin-sensitive pathway required for the nutrient-sensitive interaction between raptor and mTOR

21 January 2018

1 reference

PRAS40 regulates mTORC1 kinase activity by functioning as a direct inhibitor of substrate binding

21 January 2018

1 reference

PRAS40 is an insulin-regulated inhibitor of the mTORC1 protein kinase

21 January 2018

1 reference

The proline-rich Akt substrate of 40 kDa (PRAS40) is a physiological substrate of mammalian target of rapamycin complex 1

21 January 2018

1 reference

PRAS40 is a target for mammalian target of rapamycin complex 1 and is required for signaling downstream of this complex

21 January 2018

1 reference

Insulin signalling to mTOR mediated by the Akt/PKB substrate PRAS40

21 January 2018

1 reference

mSin1 is necessary for Akt/PKB phosphorylation, and its isoforms define three distinct mTORC2s

21 January 2018

1 reference

Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton

21 January 2018

1 reference

Molecular organization of target of rapamycin complex 2.

21 January 2018

1 reference

Identification of Protor as a novel Rictor-binding component of mTOR complex-2

21 January 2018

1 reference

Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive

21 January 2018

1 reference

Gene expression profiling in sarcomas

21 January 2018

1 reference

IGF-I receptor signalling in transformation and differentiation

21 January 2018

1 reference

Disrupting insulin-like growth factor signaling as a potential cancer therapy

21 January 2018

1 reference

Tsc tumour suppressor proteins antagonize amino-acid-TOR signalling

21 January 2018

1 reference

The phosphoinositide 3-kinase pathway

21 January 2018

1 reference

Dual role of phosphatidylinositol-3,4,5-trisphosphate in the activation of protein kinase B

21 January 2018

1 reference

Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex

21 January 2018

1 reference

Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer

21 January 2018

1 reference

Understanding Ras: 'it ain't over 'til it's over'.

21 January 2018

1 reference

Phosphorylation and functional inactivation of TSC2 by Erk implications for tuberous sclerosis and cancer pathogenesis

21 January 2018

1 reference

The coordinate regulation of the p53 and mTOR pathways in cells

21 January 2018

1 reference

eIF4E--from translation to transformation

21 January 2018

1 reference

mTOR and S6K1 mediate assembly of the translation preinitiation complex through dynamic protein interchange and ordered phosphorylation events

21 January 2018

1 reference

Survival signalling by Akt and eIF4E in oncogenesis and cancer therapy

21 January 2018

1 reference

The Akt-mTOR tango and its relevance to cancer

21 January 2018

1 reference

Absence of S6K1 protects against age- and diet-induced obesity while enhancing insulin sensitivity

21 January 2018

1 reference

Combination mammalian target of rapamycin inhibitor rapamycin and HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycin has synergistic activity in multiple myeloma

21 January 2018

1 reference

Targeting heat-shock protein 90 improves efficacy of rapamycin in a model of hepatocellular carcinoma in mice

21 January 2018

1 reference

Combination of rapamycin and 17-allylamino-17-demethoxygeldanamycin abrogates Akt activation and potentiates mTOR blockade in breast cancer cells

21 January 2018

1 reference

Phase I trial of the novel mammalian target of rapamycin inhibitor deforolimus (AP23573; MK-8669) administered intravenously daily for 5 days every 2 weeks to patients with advanced malignancies

21 January 2018

1 reference

Docetaxel and cisplatin with granulocyte colony-stimulating factor (G-CSF) versus MVAC with G-CSF in advanced urothelial carcinoma: a multicenter, randomized, phase III study from the Hellenic Cooperative Oncology Group

21 January 2018

1 reference

Mammalian target of rapamycin as a therapeutic target in leukemia

21 January 2018

1 reference

A phase 2 clinical trial of deforolimus (AP23573, MK-8669), a novel mammalian target of rapamycin inhibitor, in patients with relapsed or refractory hematologic malignancies

21 January 2018

1 reference

Phase II study of ET-743 in advanced soft tissue sarcomas: a European Organisation for the Research and Treatment of Cancer (EORTC) soft tissue and bone sarcoma group trial

21 January 2018

1 reference

Rapamycin induces feedback activation of Akt signaling through an IGF-1R-dependent mechanism.

21 January 2018

1 reference

Efficacy of RAD001 (everolimus) and octreotide LAR in advanced low- to intermediate-grade neuroendocrine tumors: results of a phase II study

21 January 2018

1 reference

The serine/threonine kinase Pim-1

21 January 2018

1 reference

Pim and Akt oncogenes are independent regulators of hematopoietic cell growth and survival

21 January 2018

1 reference

Advanced soft-tissue sarcoma: a disease that is potentially curable for a subset of patients treated with chemotherapy

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.2217/FON.09.9

1 reference

20 August 2017

1 reference